1. Home
  2. ICON vs HCWB Comparison

ICON vs HCWB Comparison

Compare ICON & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Icon Energy Corp.

ICON

Icon Energy Corp.

HOLD

Current Price

$1.07

Market Cap

2.7M

Sector

N/A

ML Signal

HOLD

Logo HCW Biologics Inc.

HCWB

HCW Biologics Inc.

HOLD

Current Price

$0.37

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICON
HCWB
Founded
2023
2018
Country
Greece
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7M
2.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
ICON
HCWB
Price
$1.07
$0.37
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$22.50
$35.00
AVG Volume (30 Days)
131.4K
431.0K
Earning Date
02-24-2026
05-14-2026
Dividend Yield
4653.47%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,099,750.00
Revenue This Year
$22.33
N/A
Revenue Next Year
$23.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$0.25
52 Week High
$4.23
$17.80

Technical Indicators

Market Signals
Indicator
ICON
HCWB
Relative Strength Index (RSI) 49.30 42.18
Support Level $0.69 $0.25
Resistance Level $1.24 $0.78
Average True Range (ATR) 0.08 0.04
MACD 0.01 0.02
Stochastic Oscillator 35.08 57.16

Price Performance

Historical Comparison
ICON
HCWB

About ICON Icon Energy Corp.

Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users. The cargos carried by the company are Grains, Minerals, Iron Ore, Coal and Bauxite.

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

Share on Social Networks: